Review
In this review, the lurasidone development programme for adult and paediatric patients is described. In addition, the pharmacokinetic and pharmacodynamic characteristics of lurasidone are revisited, pivotal clinical studies conducted on both adults and children are summarized, and several clinical cases are also presented.
Original Research
This study compares the rate and extent of serum and sebum concentration of super-bioavailable itraconazole and conventional itraconazole at different dosing to determine their efficacy and safety in patients with dermatophytosis.
Review
This article reviews an updated therapeutic algorithm for heart failure with reduced ejection fraction (HFrEF) with a special focus on the therapeutic value of adding an mineralocorticoid receptor antagonist, changing an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for an angiotensin
II receptor-neprilysin inhibitor and incorporating an sodium–glucose cotransporter 2 inhibitor in patients with HFrEF.
Review
This review provides comprehensive information about vericiguat in terms of its differential mechanism of action and clinical data particularly focused on the VICTORIA trial.
Review
This article provides an overview of the main pathophysiological characteristics of heart failure with preserved ejection fraction (HFpEF), the considered diverse biological effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in this context and the supporting clinical evidence of SGLT2i in patients with HFpEF with a focus on the EMPEROR-Preserved and DELIVER trials.
